quinazolines has been researched along with arsenic trioxide in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaplow, R | 1 |
| Baek, JH; Cha, SJ; Kim, H; Min, YJ; Noh, EK; Park, JH; Park, MJ; Won, JH | 1 |
| Berger, W; Ferk, F; Heffeter, P; Hoda, MA; Jungwirth, U; Karnthaler-Benbakka, C; Knasmüller, S; Kowol, CR; Kryeziu, K | 1 |
| Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS | 1 |
| Fang, Q; Lu, T; Ma, D; Wang, J; Wang, W; Wei, D; Yu, K; Zhang, T; Zhang, Z | 1 |
1 review(s) available for quinazolines and arsenic trioxide
| Article | Year |
|---|---|
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
4 other study(ies) available for quinazolines and arsenic trioxide
| Article | Year |
|---|---|
Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines | 2010 |
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
Topics: Acid Anhydride Hydrolases; Animals; Arsenic Trioxide; Arsenicals; BRCA1 Protein; DNA Breaks, Double-Stranded; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasms; Oxides; Phosphorylation; Quinazolines; Rad51 Recombinase; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Biomarkers, Tumor; Caspases; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Leukemia, Promyelocytic, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Prognosis; Quinazolines; Retinoic Acid Receptor alpha; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |